Amended Statement of Ownership (sc 13g/a)
17 2월 2016 - 3:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13d-1 (b),
(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
(Amendment No. 1) *
| TetraLogic
Pharmaceuticals Corporation |
| (Name of Issuer) |
| |
| Common Stock |
| (Title of Class of Securities) |
| |
| 88165U109 |
| (CUSIP Number) |
| |
| December 31, 2015 |
| (Date of Event Which Requires Filing of This Statement) |
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
*The remainder of this cover page shall be
filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
| CUSIP
NO. 88165U109 |
13 G |
Page 2 of 10 Pages |
| 1 |
NAMES OF REPORTING PERSONS
Nextech III Oncology, LPCI |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
¨ (b)
x (1) |
| 3 |
SEC USE ONLY |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland |
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5 |
SOLE VOTING POWER
1,133,919 shares
|
| 6 |
SHARED VOTING POWER
0 shares
|
| 7 |
SOLE DISPOSITIVE POWER
1,133,919 shares
|
| 8 |
SHARED DISPOSITIVE POWER
0 shares
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 1,133,919 shares of Common Stock |
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES* ¨ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.58%(2) |
| 12 |
TYPE OF REPORTING PERSON*
PN |
| (1) | This Schedule 13G is filed by Nextech III Oncology, LPCI (“Nextech III LP”), Nextech
III GP Ltd. (“Nextech III GP”), Alfred Scheidegger (“Scheidegger”), Thomas Lips (“Lips”) and
Marco Weibel (“Weibel” together with Nextech III LP, Nextech III GP, Scheidegger and Lips, collectively, the “Reporting
Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
| (2) | The 1,133,919 shares of Common Stock held by the Reporting Person represent 4.58% of the
Issuer’s outstanding Common Stock as of December 31, 2015, based on a total of 24,769,083 shares of Common Stock outstanding
as of October 30, 2015, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 4, 2015. |
| CUSIP NO. 88165U109 |
13 G |
Page 3 of 10 Pages |
| 1 |
NAMES OF REPORTING PERSONS
Nextech III GP Ltd. |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨ (b) x (1) |
| 3 |
SEC USE ONLY |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland |
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5 |
SOLE VOTING POWER
1,133,919 shares
|
| 6 |
SHARED VOTING POWER
0 shares
|
| 7 |
SOLE DISPOSITIVE POWER
1,133,919 shares
|
| 8 |
SHARED DISPOSITIVE POWER
0 shares
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 1,133,919 shares |
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES* ¨ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.58%(2) |
| 12 |
TYPE OF REPORTING PERSON*
OO |
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status
as a “group” for purposes of this Schedule 13G. |
| (2) | The 1,133,919 shares of Common Stock held by the Reporting Person represent 4.58% of the Issuer’s
outstanding Common Stock as of December 31, 2015, based on a total of 24,769,083 shares of Common Stock outstanding as of October
30, 2015, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 4, 2015. |
| CUSIP NO. 88165U109 |
13 G |
Page 4 of 10 Pages |
| 1 |
NAMES OF REPORTING PERSONS
Alfred Scheidegger |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨ (b)
x (1) |
| 3 |
SEC USE ONLY |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland |
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares
|
| 6 |
SHARED VOTING POWER
1,133,919 shares
|
| 7 |
SOLE DISPOSITIVE POWER
0 shares
|
| 8 |
SHARED DISPOSITIVE POWER
1,133,919 shares
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 1,133,919 shares |
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES* ¨ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.58%(2) |
| 12 |
TYPE OF REPORTING PERSON*
IN |
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status
as a “group” for purposes of this Schedule 13G. |
| (2) | The 1,133,919 shares of Common Stock held by the Reporting Person represent 5.48% of the Issuer’s
outstanding Common Stock as of December 31, 2015, based on a total of 24,769,083 shares of Common Stock outstanding as of October
30, 2015, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 4, 2015. |
| CUSIP NO. 88165U109 |
13 G |
Page 5 of 10 Pages |
| 1 |
NAMES OF REPORTING PERSONS
Thomas Lips |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨ (b)
x (1) |
| 3 |
SEC USE ONLY |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland |
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares
|
| 6 |
SHARED VOTING POWER
1,133,919 shares
|
| 7 |
SOLE DISPOSITIVE POWER
0 shares
|
| 8 |
SHARED DISPOSITIVE POWER
1,133,919 shares
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 1,133,919 shares |
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES* ¨ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.58% (2) |
| 12 |
TYPE OF REPORTING PERSON*
IN |
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status
as a “group” for purposes of this Schedule 13G. |
| (2) | The 1,133,919 shares of Common Stock held by the Reporting Person represent 4.58% of the Issuer’s
outstanding Common Stock as of December 31, 2015, based on a total of 24,769,083 shares of Common Stock outstanding as of October
30, 2015, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 4, 2015. |
| CUSIP NO. 88165U109 |
13 G |
Page 6 of 10 Pages |
| 1 |
NAMES OF REPORTING PERSONS
Marco Weibel |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨ (b)
x (1) |
| 3 |
SEC USE ONLY |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland |
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares
|
| 6 |
SHARED VOTING POWER
1,133,919 shares
|
| 7 |
SOLE DISPOSITIVE POWER
0 shares
|
| 8 |
SHARED DISPOSITIVE POWER
1,133,919 shares
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 1,133,919 shares |
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES* ¨ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.58% (2) |
| 12 |
TYPE OF REPORTING PERSON*
IN |
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status
as a “group” for purposes of this Schedule 13G. |
| (2) | The 1,133,919 shares of Common Stock held by the Reporting Person represent 4.58% of the Issuer’s
outstanding Common Stock as of December 31, 2015, based on a total of 24,769,083 shares of Common Stock outstanding as of October
30, 2015, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 4, 2015. |
Introductory Note: This statement on Schedule 13G is filed by the
Reporting Persons with the Commission in respect of shares of Common Stock (“Common Stock”), of TetraLogic Pharmaceuticals
Corporation, a Delaware corporation (the “Issuer”).
Item 1
| (a) |
Name of Issuer: |
TetraLogic Pharmaceuticals Corporation |
| |
|
|
| (b) |
Address of Issuer’s |
|
| |
Principal Executive Offices: |
343 Phoenixville Pike |
| |
|
Malvern, PA 19355 |
Item 2
| (a) | Name of Reporting Persons Filing: |
| 1. | Nextech III Oncology, LPCI (“Nextech III LP”) |
| 2. | Nextech III GP Ltd. (“Nextech III GP”) |
| 3. | Alfred Scheidegger (“Scheidegger”) |
| 5. | Marco Weibel (“Weibel”) |
| (b) |
Address of Principal Business Office: |
c/o Nextech Invest Ltd. |
| |
|
Turnerstrasse 26 |
| |
|
8006 Zurich |
| |
|
Switzerland |
| |
Nextech III LP |
Switzerland |
|
| |
Nextech III GP |
Switzerland |
|
| |
Scheidegger |
Switzerland |
|
| |
Lips |
Switzerland |
|
| |
Weibel |
Switzerland |
|
| (d) |
Title of Class of Securities: |
Common Stock |
| (e) |
CUSIP Number: |
88165U109 |
The following information
with respect to the beneficial ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is
provided as of December 31, 2015:
| Reporting Persons | |
Shares
Held
Directly (1) | | |
Sole
Voting
Power | | |
Shared
Voting
Power (1) | | |
Sole
Dispositive
Power | | |
Shared
Dispositive
Power (1) | | |
Beneficial
Ownership
(1) | | |
Percentage
of
Class (1, 3) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| Nextech III LP | |
| 1,133,919 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 4.58 | % |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Nextech III GP (2) | |
| 0 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 4.58 | % |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Scheidegger (2) | |
| 0 | | |
| 0 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 1,133,919 | | |
| 4.58 | % |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Lips (2) | |
| 0 | | |
| 0 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 1,133,919 | | |
| 4.58 | % |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Weibel (2) | |
| 0 | | |
| 0 | | |
| 1,133,919 | | |
| 0 | | |
| 1,133,919 | | |
| 1,133,919 | | |
| 4.58 | % |
| (1) | Consists of 1,133,919 shares of Common Stock of the Issuer. |
| (2) | The shares are held by Nextech III LP. Nextech III GP serves as the sole general partner of Nextech
III LP and has sole voting and investment control over the shares owned by Nextech III LP and may be deemed to own beneficially
the shares held by Nextech III LP. Nextech III GP owns no securities of the Issuer directly. Scheidegger, Lips and Weibel are managing
members of Nextech III GP and share voting and dispositive power over the shares held by Nextech III LP, and may be deemed to own
beneficially the shares held by Nextech III LP. The managing members own no securities of the Issuer directly. |
| (3) | The 1,133,919 shares of Common Stock held by the Reporting
Person represent 4.58% of the Issuer’s outstanding Common Stock as of December 31, 2015, based on a total of 24,769,083
shares of Common Stock outstanding as of October 30, 2015, as disclosed in the Issuer’s Form 10-Q filed with the SEC on
November 4, 2015. |
| Item 5 | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report
the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the
class of securities, check the following: x
| Item 6 | Ownership of More Than Five Percent on Behalf of Another
Person. |
Not applicable.
| Item 7 | Identification and Classification of the Subsidiary
which Acquired the Security Being Reported on by the Parent Holding Company. |
Not
applicable.
| Item 8 | Identification and Classification of Members of the
Group. |
Not
applicable.
| Item 9 | Notice of Dissolution of Group. |
Not
applicable.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in the attached statement on Schedule 13G
is true, complete and correct.
Dated: February 16, 2016
NexTech III Oncology, LPCI
By: Nextech III GP Ltd.
Its: General Partner
| By: |
/s/ Alfred Scheidegger |
|
| |
Alfred Scheidegger, Managing Member |
|
| |
|
|
| By: |
/s/ Thomas Lips |
|
| |
Thomas Lips, Managing Member |
|
| |
|
|
| Nextech III GP Ltd. |
|
| |
|
|
| By: |
/s/ Alfred Scheidegger |
|
| |
Alfred Scheidegger, Managing Member |
|
| |
|
|
| /s/ Alfred Scheidegger |
|
| Alfred Scheidegger |
|
| |
|
|
| /s/ Thomas Lips |
|
| Thomas Lips |
|
| |
|
| /s/ Marco Weibel |
|
| Marco Weibel |
|
Exhibit(s):
| CUSIP No. 88165U109 |
13G |
Exhibit 99.1 |
EXHIBIT A
JOINT FILING STATEMENT
We, the undersigned, hereby express our agreement
that the attached statement on Schedule 13G relating to the Common Stock of TetraLogic Pharmaceuticals Corporation is filed on
behalf of each of us.
Dated: February 16, 2016
NexTech III Oncology, LPCI
By: Nextech III GP Ltd.
Its: General Partner
| By: |
/s/ Alfred Scheidegger |
|
| |
Alfred Scheidegger, Managing Member |
|
| |
|
|
| By: |
/s/ Thomas Lips |
|
| |
Thomas Lips, Managing Member |
|
| |
|
|
| Nextech III GP Ltd. |
|
| |
|
|
| By: |
/s/ Alfred Scheidegger |
|
| |
Alfred Scheidegger, Managing Member |
|
| |
|
|
| /s/ Alfred Scheidegger |
|
| Alfred Scheidegger |
|
| |
|
|
| /s/ Thomas Lips |
|
| Thomas Lips |
|
| |
|
|
| /s/ Marco Weibel |
|
| Marco Weibel |
|
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
